Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trialJong Wook Lee, Yasuo Mori, Jin Seok Kim et al.|The Lancet Haematology|2023Cited by 88
Phase 3 randomized <scp>COMMODORE</scp> 2 trial: Crovalimab versus eculizumab in patients with <scp>paroxysmal nocturnal hemoglobinuria</scp> naive to complement inhibitionAlexander Röth, Bing Han, Xiaoqin Wang et al.|American Journal of Hematology|2024Cited by 46